NY-ESO-1 as a potential immunotherapeutic target in renal cell carcinoma

Eva Giesen; Lucia B. Jilaveanu; Fabio Parisi; Yuval Kluger; Robert L. Camp; Harriet M. Kluger

doi:10.18632/oncotarget.2101

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Clinical Research Papers:

NY-ESO-1 as a potential immunotherapeutic target in renal cell carcinoma

Eva Giesen, Lucia B. Jilaveanu, Fabio Parisi, Yuval Kluger, Robert L. Camp and Harriet M. Kluger _

PDF | HTML | How to cite

Oncotarget. 2014; 5:5209-5217. https://doi.org/10.18632/oncotarget.2101

Metrics: PDF 1965 views | HTML 2142 views | ?

Abstract

Eva Giesen1,*, Lucia B. Jilaveanu1,*, Fabio Parisi2, Yuval Kluger2, Robert L. Camp2 and Harriet M. Kluger1

1 Yale Cancer Center, Yale University School of Medicine, New Haven, CT, U.S

2 Department of Pathology, Yale University School of Medicine, New Haven, CT, U.S

* These authors contributed equally to this work

Correspondence:

Harriet M. Kluger , email:

Keywords: Cancer Testis Antigens, drug targets, kidney cancer, clear cell carcinoma, adoptive cell therapy

Received: April 15, 2014 Accepted: June 12, 2014 Published: June 13, 2014

Abstract

Background: Novel immune therapies targeting tumor specific antigens are being developed. Our purpose was to determine expression of the cancer testes antigen NY-ESO-1 in renal cell carcinoma (RCC), as NY-ESO-1 targeting approaches, particularly adoptive cell therapy, have not been evaluated in this disease.

Methods: We employed tissue microarrays containing >300 unique RCC cases and adjacent benign renal tissue to determine NY-ESO-1 expression using a quantitative immunofluorescence method. In addition, we studied NY-ESO-1 expression in 35 matched primary and metastatic RCC specimens to assess concordance between different tumor sites.

Results: NY-ESO-1 was highly expressed in a subset of RCCs. Expression in primary RCC specimens was significantly higher than adjacent normal renal tissue (P<0.0001) and higher in clear cell carcinomas than papillary RCC (P<0.0001). Expression levels in metastatic specimens were higher than in matched primary samples (P=0.0018), and the correlation between the two sites was modest (χ2=3.5, p=0.06).

Conclusions: Aberrant NY-ESO-1 expression seen in clear cell RCC suggests that NY-ESO-1 targeting approaches should be studied in this disease. Expression is higher in metastatic sites, and discordance between primary and metastatic sites in some patients suggests that patient selection for these therapies should be based on expression in metastatic rather than nephrectomy specimens.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 2101

Publication Alerts

Clinical Research Papers:

NY-ESO-1 as a potential immunotherapeutic target in renal cell carcinoma

Abstract